Literature DB >> 24082421

Fibromuscular dysplasia of the renal artery as a cause of secondary hypertension.

Aneley Y Hundae1, Christopher A Hebert, Jeffrey M Schussler.   

Abstract

Fibromuscular dysplasia is an uncommon cause of secondary hypertension. When the resulting hypertension cannot be successfully treated with medications, balloon angioplasty has been shown to be successful by disrupting the "webs" of tissue in the renal artery. We present a case of secondary hypertension due to fibromuscular dysplasia and the successful treatment with balloon angioplasty.

Entities:  

Year:  2013        PMID: 24082421      PMCID: PMC3777088          DOI: 10.1080/08998280.2013.11929019

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  5 in total

Review 1.  Fibromuscular dysplasia.

Authors:  David P Slovut; Jeffrey W Olin
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

2.  Percutaneous transluminal renal artery angioplasty using the coaxial technique. Ten years of experience from 591 procedures in 419 patients.

Authors:  N E Kløw; D Paulsen; K Vatne; B Rokstad; B Lien; P Fauchald
Journal:  Acta Radiol       Date:  1998-11       Impact factor: 1.990

3.  Revascularisation of renal artery stenosis caused by fibromuscular dysplasia: effects on blood pressure during 7-year follow-up are influenced by duration of hypertension and branch artery stenosis.

Authors:  A Alhadad; I Mattiasson; K Ivancev; A Gottsäter; B Lindblad
Journal:  J Hum Hypertens       Date:  2005-10       Impact factor: 3.012

Review 4.  Contemporary management of fibromuscular dysplasia.

Authors:  Jeffrey W Olin; Matthew Pierce
Journal:  Curr Opin Cardiol       Date:  2008-11       Impact factor: 2.161

5.  Fibromuscular hyperplasia: extension of the disease and therapeutic outcome. Results of the University Hospital Zurich Cooperative Study on Fibromuscular Hyperplasia.

Authors:  T F Lüscher; H M Keller; H G Imhof; P Greminger; U Kuhlmann; F Largiadèr; E Schneider; J Schneider; W Vetter
Journal:  Nephron       Date:  1986       Impact factor: 2.847

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.